Dengue (tetravalent) vaccine is under clinical development by Panacea Biotec and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Dengue (tetravalent) vaccine’s likelihood of approval (LoA) and phase transition for Dengue Fever took place on 28 May 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Dengue (tetravalent) vaccine Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Dengue (tetravalent) vaccine overview

Vaccine is under development for the prevention of dengue in adult and pediatrics. The therapeutic candidate is a recombinant lyophilized live attenuated vaccine which is formulated as a solution and administered through subcutaneous route. It is a recombinant chimeric tetravalent dengue vaccine.

Panacea Biotec overview

Panacea Biotec (Panacea) is a research-based health management company that research, develops, manufactures, distributes and markets pharmaceuticals, vaccines and biosimilars. Its vaccines portfolio includes trivalent and bivalent oral polio vaccine, and vaccines for diphtheria, tetanus, pertussis, Hepatitis B and haemophilus influenzae Type B. Its pharmaceutical formulations span across therapeutic areas, including oncology, nephrology, orthopedics, gastroenterology, pain management, diabetes, blood related, and organ transplantation, among others. The company also offers contract research and manufacturing services. Panacea operates manufacturing facilities in Baddi, Himachal Pradesh and Lalru, Punjab. It has presence in India, Switzerland, and Germany. Panacea is headquartered in New Delhi, India.

Quick View Dengue (tetravalent) vaccine LOA Data

Report Segments
  • Innovator
Drug Name
  • Dengue (tetravalent) vaccine
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Infectious Disease
Key Developers
  • Sponsor Company: Panacea Biotec
  • Originator: U.S. National Institutes of Health
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.